Page 1

Q3 2026 Financial Report Summary of financial performance 2) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Order intake 8,781 8,477 25,388 25,470 33,943 34,025 Organic change, % 2.6 4.7 4.2 4.0 3.5 Net sales 8,446 8,226 24,270 24,783 34,455 34,969 Organic change, % 2.1 9.5 2.5 6.6 4.9 Adjusted gross profit 4,343 4,051 12,817 12,570 17,854 17,607 Margin, % 51.4 49.2 52.8 50.7 51.8 50.4 Adjusted EBITDA 1,711 1,501 4,825 4,353 7,054 6,581 Margin, % 20.3 18.2 19.9 17.6 20.5 18.8 Adjusted EBITA 1,278 1,079 3,580 3,071 5,389 4,880 Margin, % 15.1 13.1 14.8 12.4 15.6 14.0 Adjusted EBIT 1,182 986 3,304 2,776 5,021 4,494 Margin, % 14.0 12.0 13.6 11.2 14.6 12.9 Operating profit (EBIT) 1,108 952 3,099 2,418 4,470 3,789 Margin, % 13.1 11.6 12.8 9.8 13.0 10.8 Profit before tax 974 789 2,698 1,938 3,905 3,145 Net profit for the period 726 576 1,967 1,407 2,836 2,276 Adjusted net profit for the period 850 668 2,316 1,880 3,529 3,093 Margin, % 10.1 8.1 9.5 7.6 10.2 8.8 Adjusted earnings per share, SEK 3.10 2.42 8.48 6.84 12.93 11.29 Earnings per share, SEK 2.64 2.08 7.20 5.10 10.39 8.29 Cash flow from operating activities 1,567 1,084 3,965 2,395 5,519 3,949 Free cash flow 1,302 793 3,145 1,462 4,335 2,652 1) For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9 2) See page 3 for calculations of adjusted performance measures. Comments from Mattias Perjos, CEO Increased profitability, strong cash flow and higher customer satisfaction “We delivered increased profitability and strong cash flow during the third quarter . Th is was partly driven by solid sales growth in Acute Care Therapies while Surgical Workflows reported stable order intake, mainly within operating room equipment. The situation for Life Science remains mixed – the high - margin Sterile Transfer category performed strongly, while the project - based and capital - intensive product category of WIS, which includes washer - disinfectors, was impacted by the persistent ly low level of investment activity in the pharma segment. The adjusted EBITA margin strengthened sharply, rising to 15.1%, and was positively impacted by tariff refunds of SEK 45 M and year - on - year currency effects of approximately SEK 36 M. Even excluding these factors, the margin improved by more than 1 percentage point to 14.3%, which reflect s the sustained positive underlying performance of the operations. The improvement was driven by a favorable mix, price discipline and productivity improvements . Improved profitability, together with a positive development in working capital, contributed to strong cash flow. We initiated the launch of Cardiohelp II – the next generation of our ECLS therapy – in CE countries and Hong Kong during the quarter , and c ustomer response has been very positive. We also received 510(k) clearance for a new Edi catheter, which can be used with our ventilators to provide breathing support to premature infants weighing as little as 500 grams. It is increasingly important for us as a trusted partner in healthcare to show how our solutions can help increase productivity. During the quarter, we launched Torin Plan Optimizer, an AI - powered system designed to manage resources more efficiently and make surgical workflows more predictable. We also continue to make clear progress on sustainability, reducing Scope 1 and 2 greenhouse gas emissions by over 20% year over year. Getinge’s greatest strength lies in the work my colleagues around the world do every day in close collaboration with our cust omers. Against the backdrop of an uncertain global environment, I am therefore particularly pleased that we have achieved all - time highs in both customer satisfaction and employee engagement. Although organic net sales growth year to date is somewhat below the guidance , our ongoing dialogue with customers supports our decision to maintain the full - year 2026 outlook of 3 – 5% organic net sales growth. ” Outlook 2026: Net sales for 2026 are expected to increase by 3 – 5% organically, adjusted for the phase - out of Surgical Perfusion 1) (Unchanged) 1,111 July – September 2026 in brief • Net sales increased organically by 2.1% (9.5) and the order intake rose by 2.6% organically (4.7) • Adjusted gross profit amounted to SEK 4,343 M (4,051) and the margin was 51.4% (49.2) • Adjusted EBITA was SEK 1,278 M (1,079) and the margin 15.1% (13.1) • Adjusted earnings per share amounted to SEK 3.10 (2.42) • Free cash flow amounted to SEK 1,302 M (793) January – September 2026 in brief • Net sales increased organically by 2.5% (6.6) and the order intake rose by 4.2% organically (4.0) • Adjusted gross profit amounted to SEK 12,817 M (12,570) and the margin was 52.8% (50.7) • Adjusted EBITA was SEK 3,580 M (3,071) and the margin 14.8% (12.4) • Adjusted earnings per share amounted to SEK 8.48 (6.84) • Free cash flow amounted to SEK 3,145 M (1,462)

Page 2

2 | Q3 2026 Report Group performance Order intake Net sales Net sales – bridge between Q3 2025 and Q3 2026 Order intake business areas, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Acute Care Therapies 4,501 4,375 2.4 13,247 13,682 2.3 17,786 18,220 Life Science 1,224 1,232 - 1.4 3,372 3,264 7.1 4,360 4,252 Surgical Workflows 3,056 2,869 4.5 8,768 8,524 6.1 11,797 11,553 Total 8,781 8,477 2.6 25,388 25,470 4.2 33,943 34,025 Order intake regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 3,996 3,781 3.8 11,622 11,634 5.4 15,417 15,429 APAC 1,668 1,615 2.2 4,633 4,782 1.9 6,162 6,311 EMEA 3,116 3,080 1.3 9,133 9,053 3.9 12,364 12,285 Total 8,781 8,477 2.6 25,388 25,470 4.2 33,943 34,025 Net sales business areas, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Acute Care Therapies 4,516 4,339 4.5 13,081 13,594 2.0 18,161 18,675 Life Science 1,066 1,097 - 3.6 3,170 3,171 3.5 4,497 4,498 Surgical Workflows 2,864 2,789 0.7 8,019 8,018 2.9 11,796 11,796 Total 8,446 8,226 2.1 24,270 24,783 2.5 34,455 34,969 Net sales regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 3,886 3,723 2.8 11,213 11,617 1.8 15,282 15,686 APAC 1,563 1,655 - 6.5 4,405 4,849 - 4.3 6,498 6,943 EMEA 2,997 2,848 6.3 8,652 8,317 7.4 12,675 12,340 Total 8,446 8,226 2.1 24,270 24,783 2.5 34,455 34,969 Net sales specified by capital goods and recurring revenue, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Capital goods 2,498 2,675 - 6.3 7,071 7,785 - 5.1 11,254 11,968 Recurring revenue 1) 5,948 5,551 6.2 17,199 16,999 6.0 23,201 23,001 Total 8,446 8,226 2.1 24,270 24,783 2.5 34,455 34,969 • Acute Care Therapies increased its net sales organically, primarily due to ECLS therapy consumables, intra - aortic balloon pumps in Cardiac Assist and stents. • Organic net sales for Life Science fell slightly following a continuing decline in WIS and despite robust growth in Sterile Transfer. • In Surgical Workflows, organic net sales rose slightly following growth in Infection Control and Digital Health Solutions. • Positive organic growth in EMEA and Americas, with particularly strong sales in the US, France and Sweden. Sales declined in APAC, primarily driven by China and Japan. • Recurring revenues increased in the quarter, driven by, for example, ECLS therapy, Sterile Transfer and service. Sales of capital goods declined in the quarter, above all related to WIS in Life Science. • Net sales increased by SEK 220 M, corresponding to 2.7%. • Exchange rates had an impact of SEK +82M on sales, corresponding to +1.0%. • Successful efforts with price adjustments and volumes had an impact of SEK +173 M on sales, corresponding to + 2.1%. • The organic order intake for Acute Care Therapies increased, primarily in ECLS therapy consumables , Cardiac Assist and EVH consumables. • Life Science’s organic order intake declined slightly during the quarter. The positive performance in Bio - Processing and service did not offset the continuing decline in WIS. • The organic order intake for Surgical Workflows increased, mainly driven by a strong performance in operating room equipment such as surgical tables and lamps. • Geographically, the organic order intake trend was positive in all regions, with the US performing particularly well. 1) Consumables, service and spare parts

Page 3

3 | Q3 2026 Report Earnings trend SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Net sales 8,446 8,226 24,270 24,783 34,455 34,969 Adjusted gross profit 4,343 4,051 12,817 12,570 17,854 17,607 Margin, % 51.4 49.2 52.8 50.7 51.8 50.4 Adjusted operating expenses - 2,633 - 2,550 - 7,991 - 8,217 - 10,800 - 11,026 Adjusted EBITDA 1,711 1,501 4,825 4,353 7,054 6,581 Margin, % 20.3 18.2 19.9 17.6 20.5 18.8 Depreciation, amortization and write - downs of intangible assets and tangible assets 1) - 433 - 422 - 1,245 - 1,282 - 1,665 - 1,702 Adjusted EBITA 1,278 1,079 3,580 3,071 5,389 4,880 Margin, % 15.1 13.1 14.8 12.4 15.6 14.0 A Amortization and write - down of acquired intangible assets 1) - 96 - 93 - 276 - 294 - 368 - 386 Adjusted EBIT 1,182 986 3,304 2,776 5,021 4,494 Margin, % 14.0 12.0 13.6 11.2 14.6 12.9 B Acquisition and restructuring costs - 74 - 33 - 172 - 359 - 211 - 397 C Other items affecting comparability 2) - - - 33 - - 340 - 307 Operating profit (EBIT) 1,108 952 3,099 2,418 4,470 3,789 Net financial items - 134 - 163 - 401 - 480 - 565 - 644 Profit before tax 974 789 2,698 1,938 3,905 3,145 Adjusted profit before tax (adjusted for A, B and C) 1,144 916 3,179 2,591 4,824 4,236 Margin, % 13.6 11.1 13.1 10.5 14.0 12.1 Taxes - 248 - 214 - 731 - 531 - 1,069 - 869 D Tax on adjustment items 2) - 47 - 35 - 133 - 180 - 227 - 273 Adjusted net profit for the period (adjusted for A, B, C and D) 850 668 2,316 1,880 3,529 3,093 Margin, % 10.1 8.1 9.5 7.6 10.2 8.8 Of which, attributable to Parent Company shareholders 843 658 2,310 1,863 3,522 3,076 Average number of shares, thousands 272,370 272,370 272,370 272,370 272,370 272,370 Adjusted earnings per share, SEK (adjusted for A, B, C and D) 3.10 2.42 8.48 6.84 12.93 11.29 1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write - downs) 2) See Note 6 Adjustment items Adjusted EBITA per business area 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Acute Care Therapies 975 763 2,940 2,624 4,080 3,763 Margin, % 21.6 17.6 22.5 19.3 22.5 20.2 Life Science 125 141 367 318 539 490 Margin, % 11.7 12.9 11.6 10.0 12.0 10.9 Surgical Workflows 284 263 596 453 1,221 1,077 Margin, % 9.9 9.4 7.4 5.6 10.3 9.1 Group functions and other (incl. eliminations) - 106 - 89 - 324 - 323 - 451 - 450 Total 1,278 1,079 3,580 3,071 5,389 4,880 Margin, % 15.1 13.1 14.8 12.4 15.6 14.0 1) See Note 4 Depreciation, amortization and write - downs and Note 6 Adjustment items for other items affecting comparability Adjusted EBITA – bridge between Q3 2025 and Q3 2026 • Adjusted EBITA for Acute Care Therapies rose by SEK 212 M, mainly due to continued successful price adjustments, higher sales and a favorable mix. The margin improved by 4.0 percentage points. • Life Science’s adjusted EBITA decreased by SEK - 16 M, mainly attributable to a higher selling and administrative expenses. The margin fell by 1.2 percentage points. • Adjusted EBITA for Surgical Workflows increased by SEK 21 M, mainly due to price adjustments and tariff refunds. The margin improved by 0.5 percentage points. • Costs in Group functions and other were in line with previous quarters this year, but were higher than the year - earlier quarter. • Currency effects impacted adjusted gross profit by SEK +85 M and adjusted EBITA by SEK +36 M compared with last year. • Adjusted gross profit increased by SEK 29 2 M, of which the remaining tariff refunds had an impact of approximately SEK + 45 M and tariff costs of approximately SEK - 107 M (Q3 2025 SEK - 108 M) . Coupled with continued successful price adjustments, productivity and a positive mix, the margin improved by 2 . 2 percentage points. • Adjusted EBITA increased by SEK 199 M, primarily due to improved gross profit. The margin increased by 2.0 percentage points. • Acquisition and restructuring costs ar e among other things related to the ongoing rationalizations in the organization. • Net financial items decreased to SEK - 134 M, mainly as a result of lower average interest year - on - year. • The tax rate for the first three quarters was 27.1%.

Page 4

4 | Q3 2026 Report Adjusted operating expenses ( excluding depreciation, amortization and write - downs, and other items affecting comparability) 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Selling expenses - 1,282 - 1,256 - 3,904 - 3,978 - 5,270 - 5,345 Administrative expenses - 1,033 - 990 - 3,169 - 3,100 - 4,251 - 4,182 Selling and administrative expenses - 2,315 - 2,246 - 7,073 - 7,078 - 9,521 - 9,527 Research and development costs - 336 - 286 - 982 - 913 - 1,313 - 1,244 Other operating income and expenses 18 - 17 63 - 226 34 - 255 Total - 2,633 - 2,550 - 7,991 - 8,217 - 10,800 - 11,026 1) See Note 4 Depreciation, amortization and write - downs and Note 6 Adjustment items for other items affecting comparability Research and development SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Research and development costs - 466 - 434 - 1,408 - 1,407 - 1,921 - 1,921 Amortization, depreciation and write - downs - 27 - 21 - 68 - 55 - 188 - 175 Research and development costs, gross - 494 - 454 - 1,475 - 1,462 - 2,109 - 2,096 In relation to net sales, % 5.8 5.5 6.1 5.9 6.1 6.0 Capitalized development costs 131 147 426 494 575 643 In relation to net sales, % 1.5 1.8 1.8 2.0 1.7 1.8 Research and development costs, net - 363 - 307 - 1,049 - 968 - 1,534 - 1,452 Amortization and write - down of capitalized development costs 1) - 94 - 98 - 265 - 297 - 397 - 430 1) Capitalized development projects Currency impact SEK M Jul - Sep 2026 Jan - Sep 2026 R12 Sep 2026 Net sales 82 - 1,025 - 2,048 Adjusted gross profit 85 - 583 - 1,156 Adjusted EBITDA 37 - 196 - 550 Adjusted EBITA 36 - 159 - 474 Adjusted EBIT 34 - 144 - 448 Cash flow and financial position 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Cash flow before changes in working capital 1,165 1,141 3,495 3,327 5,305 5,137 Changes in working capital 402 - 56 470 - 932 214 - 1,188 Net investments in non - current assets - 265 - 292 - 820 - 933 - 1,184 - 1,297 Free cash flow 1,302 793 3,145 1,462 4,335 2,652 Net interest - bearing cash/debt 10,397 11,061 10,397 9,840 In relation to adjusted EBITDA 1) R12M, multiple 1.5 1.6 1.5 1.5 Net interest - bearing cash/debt, excl. pension provisions 8,076 8,582 8,076 7,482 In relation to adjusted EBITDA 1) R12M, multiple 1.1 1.2 1.1 1.1 1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures • Exchange - rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK +85 M compared with last year, of which SEK +37 M in translation effects and SEK +48 M in transaction effects. • The change in adjusted EBITA attributable to currency effects was SEK +36 M, of which SEK +10 M arose from translation effects and SEK +26 M from the net of transaction effects and revaluation of operating receivables and liabilities in foreign currency. • Free cash flow increased considerably compared with last year. It was positively impacted by the strong operating profit and changes in working capital. • The financial position remains solid. • Adjusted operating expenses for selling and administration increased by 3.0%. Organically they increased by 1.8% . • The year - on - year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency. • Costs for R&D were 7.4% higher year - on - year. • Capitalized development costs were 10.9% lower compared with last year. • The year - on - year difference was mainly due to higher activity. • Amortization and write - down of capitalized development costs amounted to SEK - 94 M ( - 98), of which SEK - 6 M write - down ( - 4).

Page 5

5 | Q3 2026 Report Sustainability developments This interim report reflects Getinge’s double materiality assessment and is based on the ESRS structure to present the company’s impact, risks and opportunities from a social, environmental and governance perspective. The purpose of the sustainability KPls is to monitor trends over time. Getinge continuously works to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders. Key areas R12 Sep 2026 1) R12 Sep 2025 1) Δ, % 2) Jan - Dec 2025 Δ, % 3) Environment, Climate & Energy Scope 1 & 2 GHG emissions in production, ton CO 2 equivalents 9 ) 3,990 5,026 - 20.6 4,913 - 18.8 Total energy consumption in production, MWh 9 ) 75,705 82,375 - 8.1 80,887 - 6.4 Percentage of renewable energy of total energy, % 9 ) 72 69 3.0* 69 3.0* Water consumption in sites located in water scarce areas, m 3 4), 9 ) 117,480 107,318 9.5 114,691 2.4 Social Own workforce Employee engagement, % 5) 73.5 72 1.5* 73 0.5* Percentage of female employees, % 6) 38.6 37.9 0.7* 38.2 0.4* Percentage of female managers, % 6) 35.1 34.3 0.8* 34.1 1.0* Work Related Accident Rate, WRAR 9 ) 0.5 0.84 - 40.5 0.59 - 15.3 Consumers and end - users Regulatory compliance, audit findings per audit for quality systems 7) 0.8 - - 0.7 5.5 Product quality, field actions per SEK billion in net revenue 1.1 1.1 0 1.0 13.4 Online customer training 55,363 50,815 9.0 53,238 4.0 Governance Business ethics Percentage of employees who completed training in business ethics, % 8) 96 - - - - *) Change in percentage points 1) R12 = Rolling 12 months 2) Index R12 Sep 2026/ R12 Sep 2025 3) Index R12 Sep 2026/ Jan - Dec 2025 4) The production sites in scope are those located in areas with high or extremely high water stress according to the WRI Water Risk Atlas tool Acqueduct, which are eight sites. 5) Measured and updated every six months 6) Amount at end of period 7) Data available from 2025 . According to the previous definition of the KPI, the outcome was 1.4 audit findings for the full - year 2025 8) Outcome for Jan - Sep 2026. From 2026, the KPI represents the percentage of employees who completed Getinge’s new Code of Conduct workshop. The outcome for the previous training in business ethics was 92% for the full - year 2025 9) Four legal entities joined the Group by acquisition, and data was updated in 2025. See Getinge’s Annual Report 2025 for more information . Data for Pennamed is included from the acquisition date 2026 • Getinge’s energy efficiency measures continued to yield results in the quarter in terms both of energy consumption and of lower Scope 1 & 2 emissions from production facilities. The increase in the share of renewable electricity and gas also contributed to lower emissions for R12 Sep 2026. • Water consumption is mainly related to testing in production and therefore varies over time. The higher outcome for R12 Sep 2026 compared with last year mainly derived from increased production. • The employee engagement index was updated with the results of the employee survey conducted in Q2 2026. The outcome was 74, which reflects a continued positive trend and resulted in a score of 73.5 for employee engagement for R12 Sep 2026. • The Work Related Accident Rate (WRAR) outcome for R12 Sep 2026 continued to show a positive trend. • From 2026, the definition of the regulatory compliance KPI has been revised to focus on major observations from regulators and notified bodies only. The KPI increased slightly in R12 Sep 2026 due to the date that the audits were performed. • Training in business ethics has had a positive development R12 Sep 2026 with 96% of employees that have completed Getinge’s Code of Conduct workshop. • Sustainability reporting now includes Pennamed from the acquisition date.

Page 6

6 | Q3 2026 Report Acute Care Therapies Acute Care Therapies offers world - leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care. Order intake and net sales Order intake regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 2,315 2,261 0.5 6,888 7,380 - 1.3 9,299 9,791 APAC 978 964 - 0.3 2,726 2,785 2.9 3,523 3,583 EMEA 1,208 1,150 8.7 3,634 3,516 9.7 4,964 4,846 Total 4,501 4,375 2.4 13,247 13,682 2.3 17,786 18,220 Net sales regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 2,414 2,289 4.0 6,908 7,357 - 0.8 9,444 9,893 APAC 930 922 0.3 2,673 2,837 0.0 3,765 3,928 EMEA 1,172 1,128 9.3 3,499 3,400 10.1 4,953 4,854 Total 4,516 4,339 4.5 13,081 13,594 2.0 18,161 18,675 Net sales specified by capital goods and recurring revenue, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Capital goods 874 890 - 0.6 2,526 2,873 - 6.7 3,921 4,267 Recurring revenue 1) 3,642 3,449 5.9 10,555 10,722 4.3 14,241 14,407 Total 4,516 4,339 4.5 13,081 13,594 2.0 18,161 18,675 1) Consumables, service and spare parts Earnings trend 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Net sales 4,516 4,339 13,081 13,594 18,161 18,675 Adjusted gross profit 2,689 2,456 8,062 7,951 11,008 10,897 Margin, % 59.6 56.6 61.6 58.5 60.6 58.4 Adjusted EBITDA 1,199 972 3,573 3,271 4,918 4,616 Margin, % 26.5 22.4 27.3 24.1 27.1 24.7 Depreciation, amortization and write - downs of intangible assets and tangible assets - 223 - 209 - 632 - 647 - 838 - 853 Adjusted EBITA 975 763 2,940 2,624 4,080 3,763 Margin, % 21.6 17.6 22.5 19.3 22.5 20.2 1) See Note 4 Depreciation, amortization and write - downs and Note 6 Adjustment items for other items affecting comparability Events in the business area in the quarter • We received 510(k) clearance from the US FDA for a new Edi catheter, which can be used with Getinge’s ventilators to provide breathing support to premature infants weighing between 500 and 1,000 grams. • The launch of Cardiohelp II – Getinge’s next generation of ECLS therapy – was initiated in CE countries and Hong Kong during the quarter. C ustomer response has been very positive. • Acute Care Therapies increased its net sales organically, primarily due to ECLS therapy consumables, intra - aortic balloon pumps in Cardiac Assist and stents. • Sales grew organically in all regions. The US and India made significant contributions. • Recurring revenue increased primarily as a result of ECLS therapy consumables, stents and service. Capital goods declined, mainly driven by lower sales of ventilators despite an increase in ECLS and Cardiac Assist. • The adjusted gross margin improved by 3.0 percentage points, largely due to continued successful price adjustments, higher sales and a favorable mix. • Adjusted selling and administrative expenses increased organically by 0.5%. Inorganically, these expenses increased by 1.7%. • Adjusted EBITA for Acute Care Therapies rose by SEK 212 M, mainly due to improved gross profit. The margin improved by 4.0 percentage points. • Currency effects impacted sales by SEK +56 M, adjusted gross profit by SEK +54 M and adjusted EBITA by SEK +25 M compared with last year. • The organic order intake for Acute Care Therapies increased, primarily in consumables in ECLS therapy , Cardiac Assist and EVH. • Geographically, the organic order intake grew mainly in EMEA, following a solid performance in several countries. APAC declined slightly despite strong growth in China.

Page 7

7 | Q3 2026 Report Life Science Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research. Order intake and net sales Order intake regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 470 414 12.1 1,332 1,124 25.0 1,677 1,469 APAC 123 145 - 19.3 411 399 7.3 532 520 EMEA 631 673 - 5.8 1,629 1,742 - 4.6 2,151 2,263 Total 1,224 1,232 - 1.4 3,372 3,264 7.1 4,360 4,252 Net sales regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 412 391 4.3 1,187 1,179 6.0 1,667 1,660 APAC 122 192 - 38.5 368 438 - 12.7 532 603 EMEA 532 514 3.3 1,616 1,553 6.0 2,298 2,235 Total 1,066 1,097 - 3.6 3,170 3,171 3.5 4,497 4,498 Net sales specified by capital goods and recurring revenue, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Capital goods 284 460 - 39.1 966 1,274 - 21.6 1,564 1,872 Recurring revenue 1) 781 638 22.0 2,204 1,897 20.3 2,933 2,626 Total 1,066 1,097 - 3.6 3,170 3,171 3.5 4,497 4,498 1) Consumables, service and spare parts Earnings trend 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Net sales 1,066 1,097 3,170 3,171 4,497 4,498 Adjusted gross profit 409 401 1,231 1,208 1,699 1,676 Margin, % 38.4 36.5 38.8 38.1 37.8 37.3 Adjusted EBITDA 177 197 522 484 750 712 Margin, % 16.6 18.0 16.5 15.3 16.7 15.8 Depreciation, amortization and write - downs of intangible assets and tangible assets - 53 - 56 - 155 - 167 - 211 - 222 Adjusted EBITA 125 141 367 318 539 490 Margin, % 11.7 12.9 11.6 10.0 12.0 10.9 1) See Note 4 Depreciation, amortization and write - downs and Note 6 Adjustment items for other items affecting comparability Events in the business area in the quarter • Despite a challenging global investment climate in pharma, the WIS product segment grew in the US during the quarter. Growth was supported by the work done to optimize Getinge's US Life Science organization to meet increasing customer investments. • The nuclear medicine therapy market continues to expand rapidly and Getinge is a supplier of containment and transfer equipment to this value chain. • Life Science’s organic order intake declined slightly during the quarter. The positive performance in Bio - Processing and service did not offset the continuing decline in WIS. • The organic order intake increased only in Americas, with the US displaying positive signs through a strong performance in Bio - Processing and WIS. • Organic net sales for Life Science fell slightly following a continuing decline in WIS and despite robust growth in Sterile Transfer. • Organic sales increased in all regions except APAC, where mainly China and Japan declined. • Recurring revenue continued to show double - digit growth, while capital goods did the opposite. The decline in capital goods was primarily driven by WIS. • The adjusted gross margin increased by 1.9 percentage points, mainly attributable to a favorable mix and price adjustments. • Adjusted selling and administrative expenses increased organically by 9.1%. Inorganically, these expenses increased by 9.9%. • Life Science’s adjusted EBITA decreased by SEK 16 M, mainly attributable to higher selling and administrative expenses. The margin fell by 1.2 percentage points. • Currency effects impacted sales by SEK +8 M, adjusted gross profit by SEK +20 M and adjusted EBITA by SEK +15 M compared with last year.

Page 8

8 | Q3 2026 Report Surgical Workflows Surgical Workflows offers products and solutions to serve as an end - to - end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms. Order intake and net sales Order intake regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 1,211 1,106 7.5 3,403 3,130 14.1 4,441 4,168 APAC 568 506 13.0 1,496 1,598 - 1.2 2,106 2,208 EMEA 1,277 1,257 - 1.5 3,869 3,796 2.6 5,250 5,176 Total 3,056 2,869 4.5 8,768 8,524 6.1 11,797 11,553 Net sales regions, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Americas 1,060 1,043 - 0.4 3,118 3,081 6.4 4,171 4,133 APAC 511 540 - 6.6 1,364 1,575 - 9.4 2,201 2,412 EMEA 1,293 1,206 5.0 3,537 3,363 5.6 5,425 5,251 Total 2,864 2,789 0.7 8,019 8,018 2.9 11,796 11,796 Net sales specified by capital goods and recurring revenue, SEK M Jul - Sep 2026 Jul - Sep 2025 Org Δ, % Jan - Sep 2026 Jan - Sep 2025 Org Δ, % R12 Sep 2026 Jan - Dec 2025 Capital goods 1,340 1,325 1.3 3,579 3,638 1.9 5,769 5,829 Recurring revenue 1) 1,524 1,465 0.2 4,440 4,380 3.8 6,027 5,967 Total 2,864 2,789 0.7 8,019 8,018 2.9 11,796 11,796 1) Consumables, service and spare parts Earnings trend 1) SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Net sales 2,864 2,789 8,019 8,018 11,796 11,796 Adjusted gross profit 1,245 1,194 3,523 3,410 5,147 5,034 Margin, % 43.5 42.8 43.9 42.5 43.6 42.7 Adjusted EBITDA 439 419 1,047 915 1,828 1,697 Margin, % 15.3 15.0 13.1 11.4 15.5 14.4 Depreciation, amortization and write - downs of intangible assets and tangible assets - 155 - 155 - 451 - 463 - 608 - 619 Adjusted EBITA 284 263 596 453 1,221 1,077 Margin, % 9.9 9.4 7.4 5.6 10.3 9.1 1) See Note 4 Depreciation, amortization and write - downs and Note 6 Adjustment items for other items affecting comparability Events in the business area in the quarter • The launch of Torin Plan Optimizer, an AI - powered decision support solution for surgical planning based on operating rooms, surgeon and surgical team availability and post - operative capacity. This enables better resource utilization, which is much needed in hospitals. • The organic order intake for Surgical Workflows increased, mainly driven by a strong performance in operating room equipment such as surgical tables and lamps. • Growth was particularly strong in North America, mainly in operating tables and capital goods in Infection Control. • In Surgical Workflows, organic net sales rose slightly following growth in Infection Control and Digital Health Solutions. • Geographically, growth was high in EMEA, mainly in Surgical Workplaces and Digital Health Solutions. In APAC, the only product category that grew was Infection Control. • The increase in sales of capital goods was primarily driven by Infection Control. Recurring revenue was largely unchanged. • The adjusted gross margin increased by 0.7 percentage points, mainly due to price adjustments and tariff refunds. • Adjusted selling and administrative expenses increased organically by 1.2%. Inorganically, these expenses increased by 2.8%. • Adjusted EBITA for Surgical Workflows increased by SEK 21 M, mainly attributable to higher gross profit. The margin improved by 0.5 percentage points. • Currency effects impacted sales by SEK +18 M, adjusted gross profit by SEK +11 M and adjusted EBITA by SEK +1 M compared with last year.

Page 9

9 | Q3 2026 Report Other information Events after the end of the reporting period • Eric Honroth, President Life Science and member of the Executive Team , informed about his resign ation in early October to accept an external opportunity. Getinge has started the process of identifying a successor and will evaluate internal and external candidates. Eric Honroth will continue to serve in his current role until his departure on October 31, 2 026. To ensure continuity, an internal candidate has been appointed as interim President of Life Science, effective November 1. • The geopolitical uncertainty and changing global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations. Significant events earlier in the year During the second quarter, Getinge received a refund of previously paid US tariffs imposed under the International Emergency Economic Powers Act (IEEPA), resulting in a positive earnings impact of SEK 336 million. No other individual events occurring in earlier quarters of the year are considered to have had, or are expected to have, a material effect on the financial statements, nor are they of such significance as to be necessary for understanding the changes in the Compan y’s financial position and results of operations since the end of the latest financial year. Seasonal variations Getinge’s sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year. Transactions with related parties Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period othe r than transactions with subsidiaries. Forward - looking information This report contains forward - looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward - looking information are reasonable, no guarantee can be given that these exp ectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward - looking information, due to such factors as changed conditions regarding finances, market and competition, changes in l egal and regulatory requirements and other political measures, and fluctuations in exchange rates. Update of Organic change key ratio The definition of Organic change has been updated from the first quarter of 2026 to also adjust for phase - outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase - outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge’s website under Reports and Presentations, https://www.getinge.com/int/company/investors/reports - presentations/ . Surgical Perfusion’s sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.

Page 10

10 | Q3 2026 Report Getinge’s financial targets 2024 – 2028 and dividend policy • Average adjusted earnings per share growth: >12%* • Getinge’s dividend policy is to pay dividends of 30 - 50% of net profit to shareholders. Getinge’s sustainability targets Environment • Reduce Scope 1 and 2 emissions by 90% by 2030** • Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050** • Reduce energy consumption in production by 20% by 2030** • Reduce water consumption in sites located in water scarce areas by 20% by 2030** • No waste to landfill by 2030, excluding material required by local regulations to be landfilled Social • Employee engagement: >70% • Maintain work - related accidents in relation to working hours (Work Related Accident Rate, WRAR) at less than 1. • Ensure equal employment opportunity and non - discrimination across all levels of the organization. Follow - up % female vs male managers and employees • Quality regulatory compliance, audit results/inspection: <1.2 deviation Governance • All employees are properly trained in Business ethics *Base year 2023 **Base year 2021

Page 11

11 | Q3 2026 Report Nomination Committee ahead of 202 7 Annual General Meeting I n accordance with the principles adopted at the 2020 Annual General Meeting, the Nomination Committee shall consist of members appointed by the four largest shareholders in terms of voting rights as of August 31 of each year, based on a list of owner - registered shareholders from Euroclear Nordics AB or other reliable ownership information , a s well as the Chairman of the Board of Directors. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its m ajor shareholders, independent representative of the minority shareholders as a member of the Nomination Committee. Getinge’s Nomination Committee ahead of the 202 7 Annual General Meeting has been appointed and co nsists of the company’s Chairman Johan Malmquist, and representatives from the following shareholders , listed in order of voting power . • Carl Bennet AB: Carl Bennet, Chairman of the Nomination Committee • AMF Pension & Fonder: Sophie Larsén • Fourth Swedish National Pension Fund : Anna Magnusson • Carnegie fonder: Anna Strömberg Shareholders who wish to submit proposals to Getinge’s 202 7 Nomination Committee can contact the Nomination Committee by e - mail at valberedningen@getinge.com or by mail to the following address: Getinge AB, Att: Nomination Committee, Box 8861, SE - 402 72 Gothenburg, SWEDEN . Proposals must be received by the Nomination Committee no later than January 1 5 , 202 7, in order to ensure that they are addressed by the Committee. 202 7 Annual General Meeting Getinge AB’s Annual General Meeting will be held on April 2 0 , 202 7, in Halmstad, Sweden. Shareholders who wish to have a matter addressed at the Annual General Meeting may submit their proposal to Getinge’s Chairman of the Board via e - mail: arenden.bolagsstamma@getinge.com, or by mail to the following address: Getinge AB, Att: Bolagsstämmoärenden, Box 8861, SE - 402 72 Gothenburg, SWEDEN . To ensure inclusion in the notice and the agenda of the AGM, proposals must be received by the company no later than March 2 , 202 7 .

Page 12

12 | Q3 2026 Report Risk management Risk management Getinge operates in a global market and has a strong presence in a large number of countries. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products and services that improve people’s quality of life. Risk management framework Getinge’s three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing pro cesses and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks. Getinge has an Enterprise Risk Management (ERM) process covering all business areas, the global sales and service organization and the corporate and Group support functions. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit. Risk assessment The most relevant risks are presented in Getinge’s 2025 Annual Report, meaning that the list does not constitute a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories: • External – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities. • Operational – Risks that are largely controllable and preventable, mainly related to processes, assets and employees. • Strategic – risks that make it more difficult to achieve the strategic targets. These risks are to be managed by balancing risks and the potential for maximizing advantages.

Page 13

13 | Q3 2026 Report Assurance The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group’s operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Gro up. Gothenburg, October 21, 2026 Johan Malmquist Chairman, AGM - elected Board member Carl Bennet Vice Chairman, AGM - elected Board member Johan Bygge AGM - elected Board member Cecilia Daun Wennborg AGM - elected Board member Ulrika Dellby AGM - elected Board member Dan Frohm AGM - elected Board member Mattias Perjos President & CEO, AGM - elected Board member Kristian Samuelsson AGM - elected Board member Camilla Sylvest AGM - elected Board member Fredrik Brattborn Board member Representative of the Swedish Metalworkers’ Union Ida Ekman Board member Representative of Unionen

Page 14

14 | Q3 2026 Report AUDITOR’S REPORT Getinge AB (publ), reg. no. 556408 - 5032 Introduction We have reviewed the condensed interim report for Getinge AB (publ) as at September 30, 2026 and for the nine months period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim re port in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review. Scope of review We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 Review of Interim Financial Statements Performed by the Independent Auditor of the Entity . A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted audi ting standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with th e Swedish Annual Accounts Act regarding the Parent Company. Gothenburg, October 21, 2026 Ernst & Young AB Fredrik Norrman Authorized Public Accountant

Page 15

15 | Q3 2026 Report Consolidated financial statements Condensed consolidated income statement SEK M Note Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Net sales 2, 3 8,446 8,226 24,270 24,783 34,969 Cost of goods sold - 4,338 - 4,411 - 12,140 - 12,932 - 18,315 Gross profit 2, 3, 4 4,108 3,815 12,130 11,851 16,654 Selling expenses - 1,453 - 1,416 - 4,394 - 4,476 - 6,050 Administrative expenses - 1,128 - 1,090 - 3,446 - 3,405 - 4,587 Research and development costs - 363 - 307 - 1,049 - 968 - 1,452 Acquisition costs - 33 - 11 - 64 - 14 - 24 Restructuring costs - 41 - 23 - 108 - 345 - 374 Other operating income and expenses 18 - 17 30 - 226 - 379 Operating profit (EBIT) 3, 4 1,108 952 3,099 2,418 3,789 Net financial items 3 - 134 - 163 - 401 - 480 - 644 Profit after financial items 3 974 789 2,698 1,938 3,145 Taxes - 248 - 214 - 731 - 531 - 869 Net profit for the period 726 576 1,967 1,407 2,276 Attributable to: Parent Company shareholders 719 566 1,962 1,390 2,258 Non - controlling interests 6 10 6 17 17 Net profit for the period 726 576 1,967 1,407 2,276 Earnings per share, SEK 1) 2) 2.64 2.08 7.20 5.10 8.29 Weighted average number of shares for calculation of earnings per share (000s) 272,370 272,370 272,370 272,370 272,370 1) Before and after dilution 2) Attributable to the Parent Company shareholders Consolidated statement of comprehensive income SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Net profit for the period 726 576 1,967 1,407 2,276 Other comprehensive income Items that cannot be restated in profit for the period Actuarial gains/losses pertaining to defined - benefit pension plans 162 - 4 199 75 165 Tax attributable to items that cannot be restated in profit - 44 1 - 58 - 23 - 45 Items that can later be restated in profit for the period Translation differences 783 - 190 2,174 - 3,508 - 4,160 Hedging of net investments 95 - 35 290 - 651 - 754 Cash flow hedges 15 6 12 - 8 - 5 Tax attributable to items that can be restated in profit - 23 6 - 62 136 156 Other comprehensive income for the period, net after tax 988 - 216 2,555 - 3,980 - 4,643 Total comprehensive income for the period 1,714 360 4,522 - 2,573 - 2,367 Comprehensive income attributable to: Parent Company shareholders 1,707 351 4,516 - 2,578 - 2,373 Non - controlling interests 7 8 7 5 6 Total comprehensive income for the period 1,714 360 4,522 - 2,573 - 2,367

Page 16

16 | Q3 2026 Report Condensed consolidated balance sheet SEK M Note September 30 2026 September 30 2025 December 31 2025 Intangible assets 36,375 34,420 33,513 Tangible assets 3,584 3,526 3,469 Right - of - use assets 1,689 1,446 1,470 Financial assets 69 33 34 Deferred tax assets 894 800 792 Total non - current assets 42,611 40,225 39,278 Inventories 7,191 6,736 6,018 Accounts receivable 4,837 4,837 5,782 Other current receivables 1,803 2,142 2,026 Cash and cash equivalents 7 3,157 2,847 3,401 Total current assets 16,987 16,563 17,227 TOTAL ASSETS 59,599 56,789 56,505 Equity 32,711 29,375 29,494 Provisions for pensions, interest - bearing 7 2,322 2,479 2,358 Lease liabilities, long - term 7 1,211 1,017 1,029 Interest - bearing liabilities, long - term 7 6,811 8,545 7,893 Deferred tax liabilities 1,951 1,889 1,754 Other provisions, long - term 450 607 485 Other non - interest - bearing liabilities, long - term 499 519 452 Total long - term liabilities 13,244 15,056 13,970 Lease liabilities, current 7 500 439 452 Interest - bearing liabilities, current 7 2,710 1,428 1,510 Other provisions, current 1,621 1,644 1,564 Accounts payable 2,059 1,924 2,118 Other non - interest - bearing liabilities, current 6,755 6,923 7,398 Total current liabilities 13,644 12,358 13,042 TOTAL EQUITY AND LIABILITIES 59,599 56,789 56,505 Changes in equity for the Group SEK M Share capital Other capital provided Reserves 1) Retained earnings Total Non - controlling interests Total equity Opening balance at January 1, 2026 136 6,789 1,000 21,504 29,430 64 29,494 Total comprehensive income for the period - - 2,413 2,103 4,516 7 4,522 Dividend - - - - 1,294 - 1,294 - 12 - 1,305 Closing balance at September 30, 2026 136 6,789 3,413 22,313 32,652 59 32,711 Opening balance at January 1, 2025 136 6,789 5,752 20,328 33,005 205 33,210 Total comprehensive income for the period - - - 4 , 019 1,442 - 2, 578 5 - 2, 573 Dividend - - - - 1,253 - 1,253 - 10 - 1,2 62 Closing balance at September 30, 2025 136 6,789 1, 733 20 , 517 2 9 , 175 200 29, 375 Opening balance at January 1, 2025 136 6,789 5,752 20,328 33,005 205 33,210 Total comprehensive income for the period - - - 4,752 2,378 - 2,373 6 - 2,367 Dividend - - - - 1,253 - 1,253 - 14 - 1,267 Transactions with non - controlling interests - - - 50 50 - 133 - 83 Closing balance at December 31, 2025 136 6,789 1,000 21,504 29,430 64 29,494 1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Page 17

17 | Q3 2026 Report Condensed consolidated cash flow statement SEK M Note Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Operating activities Operating profit (EBIT) 1,108 952 3,099 2,418 3,789 Add - back of depreciation, amortization and write - downs 4 532 515 1,521 1,596 2,250 Other non - cash items 1 5 2 22 164 Add - back of restructuring costs 1) 41 23 108 326 362 Paid restructuring costs - 50 - 57 - 176 - 187 - 338 Financial items 2) - 115 - 127 - 366 - 390 - 516 Taxes paid - 353 - 171 - 694 - 457 - 574 Cash flow before changes in working capital 1,165 1,141 3,495 3,327 5,137 Changes in working capital Inventories - 177 78 - 692 - 883 - 465 Operating receivables 408 - 132 1,478 834 - 218 Operating liabilities 172 - 2 - 317 - 882 - 504 Cash flow from operating activities 1,567 1,084 3,965 2,395 3,949 Investing activities Acquisition of operations 9 - - - 1,437 - 1,580 - 1,663 Investments in intangible assets and tangible assets - 265 - 297 - 828 - 944 - 1,314 Divestment of non - current assets 0 5 9 12 17 Cash flow from investing activities - 265 - 292 - 2,256 - 2,513 - 2,960 Financing activities Change in interest - bearing liabilities - 52 317 - 174 1,495 1,000 Depreciation of lease liabilities .134 - 123 - 388 - 375 - 501 Change in long - term receivables 5 3 5 3 3 Dividend paid - - 3 - 1,305 - 1,263 - 1,267 Cash flow from financing activities - 181 193 - 1,862 - 140 - 765 Cash flow for the period 1,121 986 - 153 - 258 224 Cash and cash equivalents at the beginning of the period 2,052 1,945 3,401 2,961 2,961 Translation differences - 16 - 83 - 91 144 216 Cash and cash equivalents at the end of the period 3,157 2,847 3,157 2,847 3,401 1) Excluding write - downs on non - current assets 2) Of which interest paid and received in the quarter amounted to SEK - 108 M ( - 118) and other financial items to SEK - 7 M ( - 9)

Page 18

18 | Q3 2026 Report Note 1 Accounting policies The Group’s interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accoun ting po licies adopted are consistent with those applied for the 2025 Annual Report and should be read in conjunction with that Annua l Report. Forthcoming amendments to presentation and disclosures (IFRS 18) IFRS 18 Presentation and Disclosure in Financial Statements will be applied by the Getinge Group from January 1, 2027. The st andard will affect the presentation of the income statement, including the classification of income and expenses into the operating, investing a nd financing categories, as well as introducing new subtotals. For Getinge, the implementation is expected to result in certain reclassifications in the income statement, whereby discount effects on contingent consideration and expenses not directly attributable to the G roup’s financing will be recogni zed in the operating category, while other items that were previously recognized in net financial items for the Group have been distributed between the investing and the financing categories. The standard will also impact on the classification of interest in the presentation of the Group’s cash flow statement. The standard is not expected to impact on the Group’s overall earnings, cash flow or financial position. IFRS 18 also introduces expanded disclosure requirements in the form of management - defined performance measures. The Group is currently analyzing which of its key ratios will be impacted by th e definition and how these are to be presented and reconciled against subtotals defined by IFRS. For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not to tal correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year - earlie r period. The interim report provides alternative performance measures for monitoring the Group’s operations. Note 2 Net sales Net sales, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Capital goods 2 498 2,675 7 071 7,785 11,968 Recurring revenue Product sales 4 181 3,873 12 151 12,016 16,185 Service assignments incl. spare parts 1 767 1,678 5 048 4,983 6,815 Total recurring revenue 5 948 5,551 17 199 16,999 23,001 Total 8 446 8,226 24 270 24,783 34,969 Net sales, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Revenue recognized at a point in time Acute Care Therapies 4 199 4,043 12 204 12,752 17,499 Life Science 909 831 2 607 2,434 3,386 Surgical Workflows 2 273 2,249 6 465 6,466 9,626 Total revenue recognized at a point in time 7 380 7,124 21 277 21,652 30,512 Revenue recognized over time Acute Care Therapies Service 291 273 802 777 1,068 Profit from ongoing projects 5 0 5 - - Other revenue recognized over time 22 23 70 66 108 Total Acute Care Therapies 317 296 877 843 1,176 Life Science Service 68 63 203 198 260 Profit from ongoing projects 89 203 360 539 852 Other revenue recognized over time 0 0 0 0 0 Total Life Science 157 266 563 737 1,112 Surgical Workflows Service 525 464 1 400 1,356 1,870 Profit from ongoing projects 23 37 41 98 139 Other revenue recognized over time 43 39 113 99 160 Total Surgical Workflows 591 540 1 554 1,552 2,170 Total revenue recognized over time 1 065 1,102 2 993 3,132 4,457

Page 19

19 | Q3 2026 Report Total revenue recognized at a point in time and over time 8 446 8,226 24 270 24,783 34,969 For further information about the distribution of sales for each business area, see pages 6 - 8. Note 3 Segment overview Net sales, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acute Care Therapies 4,516 4,339 13,081 13,594 18,675 Life Science 1,066 1,097 3,170 3,171 4,498 Surgical Workflows 2,864 2,789 8,019 8,018 11,796 Total 8,446 8,226 24,270 24,783 34,969 Gross profit, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acute Care Therapies 2,568 2,339 7,715 7,586 10,420 Life Science 382 370 1,148 1,117 1,556 Surgical Workflows 1,158 1,107 3,266 3,148 4,679 Total 4,108 3,815 12,130 11,851 16,654 Operating profit (EBIT), SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acute Care Therapies 891 690 2,698 2,157 3,021 Life Science 110 125 323 261 470 Surgical Workflows 246 238 466 337 773 Group functions and other (incl. eliminations) 1) - 139 - 100 - 388 - 337 - 474 Operating profit (EBIT) 1,108 952 3,099 2,418 3,789 Net financial items - 134 - 163 - 401 - 480 - 644 Profit after financial items 974 789 2,698 1,938 3,145 1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as elimi nations. Net sales, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 EMEA 2,997 2,848 8,652 8,317 12,340 of which, Sweden 134 116 440 439 648 Americas 3,886 3,723 11,213 11,617 15,686 of which, USA 3,536 3,371 10,177 10,500 14,157 APAC 1,563 1,655 4,405 4,849 6,943 Total 8,446 8,226 24,270 24,783 34,969 Note 4 Depreciation, amortization and write - downs SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acquired intangible assets - 96 - 93 - 276 - 294 - 434 Intangible assets - 140 - 148 - 404 - 462 - 643 Right - of - use assets - 140 - 128 - 405 - 392 - 523 Tangible assets - 155 - 147 - 436 - 448 - 650 Total - 532 - 515 - 1,521 - 1,596 - 2,250 Write - downs included in total - 6 - 4 - 7 - 23 - 166 SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Cost of goods sold - 238 - 235 - 687 - 719 - 953 Selling expenses - 171 - 160 - 491 - 498 - 705 Administrative expenses - 95 - 100 - 277 - 305 - 405 Research and development costs - 27 - 21 - 68 - 55 - 175 Restructuring costs - 0 - - 19 - 12 Total - 532 515 - 1,521 - 1,596 - 2,250 Write - downs included in total - 6 - 4 - 7 - 23 - 166

Page 20

20 | Q3 2026 Report Note 5 Quarterly results SEK M Jul - Sep 2026 Apr - Jun 2026 Jan - Mar 2026 Oct - Dec 2025 Jul - Sep 2025 Apr - Jun 2025 Jan - Mar 2025 Oct - Dec 2024 Net sales 8,446 8,381 7,443 10,186 8,226 8,238 8,320 11,071 Cost of goods sold - 4,338 - 3,965 - 3,837 - 5,382 - 4,411 - 4,296 - 4,225 - 6,018 Gross profit 4,108 4,416 3,606 4,803 3,815 3,941 4,095 5,053 Operating expenses - 3,000 - 3,132 - 2,899 - 3,432 - 2,863 - 3,074 - 3,497 - 3,969 Operating profit (EBIT) 1,108 1,284 707 1,371 952 867 598 1,084 Net financial items - 134 - 133 - 135 - 164 - 163 - 147 - 170 - 173 Profit after financial items 974 1,151 573 1,207 789 721 428 911 Taxes - 248 - 312 - 170 - 338 - 214 - 194 - 124 - 243 Net profit for the period 726 839 402 869 576 527 304 668 Note 6 Adjustment items Adjusted EBITA, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acute Care Therapies 975 763 2,940 2,624 3,763 Life Science 125 141 367 318 490 Surgical Workflows 284 263 596 453 1,077 Group functions and other (incl. eliminations) - 106 - 89 - 324 - 323 - 450 Total 1,278 1,079 3,580 3,071 4,880 Adjustments of EBITA, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Specification of items affecting comparability that impact EBITA Restructuring costs, Acute Care Therapies - 26 - 16 - 39 - 282 - 293 Restructuring costs, Life Science - 2 - 3 - 7 - 16 - 22 Restructuring costs, Surgical Workflows - 13 - 4 - 62 - 48 - 59 Write - down of R&D, Acute Care Therapies - - - - - 28 Write - down of R&D, Surgical Workflows - - - - - 107 Increased provision for contingent consideration, Acute Care Therapies 1) - - - - - 179 Dissolution of provisions for contingent consideration, Life Science 1) - - - - 55 Other, Acute Care Therapies - - - 33 - - Group functions and other (incl. eliminations) - 33 - 11 - 64 - 14 - 24 Total - 74 - 33 - 205 - 359 - 656 Items affecting comparability per segment Acute Care Therapies - 26 - 16 - 72 - 282 - 500 Life Science - 2 - 3 - 7 - 16 33 Surgical Workflows - 13 - 4 - 62 - 48 - 166 Group functions and other (incl. eliminations) - 33 - 11 - 64 - 14 - 24 Total - 74 - 33 - 205 - 359 - 656 1) Reported in Other operating income and operating expenses EBITA, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Acute Care Therapies 949 748 2,868 2,342 3,264 Life Science 123 138 361 302 523 Surgical Workflows 271 260 534 405 911 Group functions and other (incl. eliminations) - 139 - 100 - 388 - 337 - 474 Total 1,204 1,045 3,375 2,712 4,223 Adjustments of EBIT, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Items affecting comparability that impact EBITA (according to above) - 74 - 33 - 205 - 359 - 656 Items affecting comparability that impact EBIT but not EBITA 1) - - - - - 48 Total - 74 - 33 - 205 - 359 - 704 1) Write - down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses

Page 21

21 | Q3 2026 Report Effect of adjustment of tax, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Amortization and write - down of acquired intangible assets 1) 96 93 276 294 386 Items affecting comparability 74 33 205 359 704 Adjustment items, total 170 127 481 653 1,091 Tax on adjustment items 2) - 47 - 35 - 133 - 180 - 273 Adjustment for tax items affecting comparability - - - - - Total - 47 - 35 - 133 - 180 - 273 1) Excluding write - downs classified as items affecting comparability 2) Tax effect on tax deductible adjustment items Note 7 Consolidated net interest - bearing debt SEK M September 30 2026 September 30 2025 December 31 2025 Interest - bearing liabilities, current 2,710 1,428 1,510 Interest - bearing liabilities, long - term 6,811 8,545 7,893 Provisions for pensions, interest - bearing 2,322 2,479 2,358 Lease liabilities, current 500 439 452 Lease liabilities, long - term 1,211 1,017 1,029 Interest - bearing liabilities 13,554 13,908 13,241 Less cash and cash equivalents - 3,157 - 2,847 - 3,401 Net interest - bearing cash/debt 10,397 11,061 9,840 Note 8 Key figures for the Group Financial and operative key figures Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Key figures based on Getinge’s financial targets Adjusted earnings per share 1) , SEK 3.10 2.42 8.48 6.84 11.29 Growth in adjusted earnings per share 1) , % 28.1 7.9 24.0 6.1 - 3.7 Other operative and financial key figures Organic growth in order intake, % 2.6 4.7 4.2 4.0 3.5 Organic growth in net sales, % 2.1 9.5 2.5 6.6 4.9 Gross margin, % 48.6 46.4 50.0 47.8 47.6 Selling expenses, % of net sales 17.2 17.2 18.1 18.1 17.3 Administrative expenses, % of net sales 13.3 13.2 14.2 13.7 13.1 Research and development costs, gross as a % of net sales 5.8 5.5 6.1 5.9 6.0 Operating margin, % 13.1 11.6 12.8 9.8 10.8 EBITDA, SEK M 1,636 1,468 4,620 4,014 6,039 Average number of shares, thousands 272,370 272,370 272,370 272,370 272,370 Number of shares at the end of the period, thousands 272,370 272,370 272,370 272,370 272,370 Interest - coverage ratio, multiple 13.2 11.6 11.2 Net debt/equity ratio, multiple 0.32 0.38 0.33 Net debt/Rolling 12m adjusted EBITDA, multiple 1.5 1.6 1.5 Capital employed, SEK M 41,135 41,417 40,934 Return on capital employed, % 12.2 11.6 11.0 Return on equity, % 9.2 6.8 7.5 Equity/assets ratio, % 54.9 51.7 52.2 Equity per share, SEK 120.10 107.85 108.28 Number of employees 11,847 11,794 11,670 1) Before and after dilution

Page 22

22 | Q3 2026 Report Alternative performance measures Alternative performance measures refer to financial measures used by the company’s management and investors to evaluate the G roup’s earnings and financial position and that cannot be directly read or derived from the financial statements. These financial m easures are intended to facilitate analysis of the Group’s performance. Accordingly, the alternative performance measures should be consi dered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in t his report may differ from similar measures used by other companies. Calculation of organic net sales Jul - Sep 2026 Jan - Sep 2026 Net sales 2025 8,226 24,783 Adjustment of: Divested operations and products as well as products being phased out, in the comparative period - 74 - 196 Net sales 2025 adjusted for divested operations and products 8,152 24,587 Net sales 2026 8,446 24,270 Adjustment of: Currency impact - 82 1,025 Acquired and divested operations and products as well as products being phased out. - 38 - 93 Net sales organic 2026 8,326 25,201 Adjusted gross profit, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Gross profit 4,108 3,815 12,130 11,851 16, 933 16,654 Add - back of: Depreciation, amortization and write - downs of intangible assets and tangible assets 235 235 687 719 921 953 Other items affecting comparability - - - - - Adjustment for write - downs included in other items affecting comparability - - - - - Adjusted gross profit 4,343 4,051 12,817 12,570 17,854 17,607 Adjusted EBITDA, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Operating profit (EBIT) 1,108 952 3,099 2,418 4,470 3,789 Add - back of: Depreciation, amortization and write - downs of intangible assets and tangible assets 433 422 1,245 1,302 1,807 1,864 Amortization and write - down of acquired intangible assets 96 93 276 294 368 386 Other items affecting comparability - - 33 - 340 307 Acquisition and restructuring costs 74 33 172 359 211 397 Adjustment for write - downs included in other items affecting comparability and restructuring costs - 0 - - 19 - 143 - 162 Adjusted EBITDA 1,711 1,501 4,825 4,353 7,054 6,581 Adjusted EBITA, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Operating profit (EBIT) 1,108 952 3,099 2,418 4,470 3,789 Add - back of: Amortization and write - down of acquired intangible assets 96 93 276 294 368 386 Other items affecting comparability - - 33 - 340 307 Acquisition and restructuring costs 74 33 172 359 211 397 Adjusted EBITA 1,278 1,079 3,580 3,071 5,389 4,880 Adjusted EBIT, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Operating profit (EBIT) 1,108 952 3,099 2,418 4,470 3,789 Add - back of: Other items affecting comparability - - 33 - 340 307 Acquisition and restructuring costs 74 33 172 359 211 397 Adjusted EBIT 1,182 986 3,304 2,776 5,021 4,494 Adjusted net profit for the period, SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Net profit for the period 726 576 1,967 1,407 2,836 2,276 Add - back of: Amortization and write - down of acquired intangible assets 96 93 276 294 368 386

Page 23

23 | Q3 2026 Report Other items affecting comparability - - 33 - 340 307 Acquisition and restructuring costs 74 33 172 359 211 397 Tax items affecting comparability - - - - - - Tax on add - back items - 47 - 35 - 133 - 180 - 227 - 273 Adjusted net profit for the period 850 668 2,316 1,880 3,529 3,093 The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information: Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Earnings (numerator), SEK M Adjusted net profit for the period 850 668 2,316 1,880 3,529 3,093 Adjusted net profit for the period attributable to non - controlling interest - 6 - 10 - 6 - 17 - 6 - 17 Adjusted net profit for the period attributable to the Parent Company shareholders, which forms the basis for calculation of adjusted earnings per share 843 658 2,310 1,863 3,522 3,076 Number of shares (denominator) Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 R12 Sep 2026 Jan - Dec 2025 Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands) 272,370 272,370 272,370 272,370 272,370 272,370 Adjusted earnings per share, SEK 3.10 2.42 8.48 6.84 12.93 11.29 The calculation of adjusted EBITA margin, adjusted for currency impact and tariff costs is based on the following information: Jul - Sep 2026 Jan - Sep 2026 R12 Sep 2026 Adjusted EBITA (numerator), SEK M Adjusted EBITA 1,278 3,580 5,389 Add - back of: Currency impact - 36 159 474 Tariffs costs 1) 62 - 78 70 Adjusted EBITA, adjusted for currency impact and tariff costs 1, 305 3, 661 5,933 Net sales (denominator) Jul - Sep 2026 Jan - Sep 2026 R12 Sep 2026 Net sales 8,446 24,270 34,455 Add - back of: Currency impact - 82 1,025 2,048 Net sales, adjusted for currency impact 8,364 25,294 36,504 Adjusted EBITA margin, adjusted for currency impact and tariff costs, % 15. 6 14. 5 16 . 3 Adjusted EBITA margin, adjusted for only tariff costs, % 15 . 9 14 . 4 15 . 8 1) Net of tariff costs and tariff refunds The calculation of adjusted EBITA margin, adjusted for currency impact and tariff refunds is based on the following information: Jul - Sep 2026 Jan - Sep 2026 R12 Sep 2026 Adjusted EBITA (numerator), SEK M Adjusted EBITA 1,278 3,580 5,389 Add - back of: Currency impact - 36 159 474 Tariff refunds - 45 - 38 1 - 381 Adjusted EBITA, adjusted for currency impact and tariff refunds 1, 197 3, 358 5,483 Net sales (denominator) Jul - Sep 2026 Jan - Sep 2026 R12 Sep 2026 Net sales 8,446 24,270 34,455 Add - back of: Currency impact - 82 1,025 2,048 Net sales, adjusted for currency impact 8,364 25,294 36,504

Page 24

24 | Q3 2026 Report Adjusted EBITA margin, adjusted for currency impact and tariff refunds, % 14. 3 13. 3 15.0 Adjusted EBITA margin, adjusted for only tariff refunds, % 14.6 13.2 14.5 Note 9 Acquisitions Acquisitions 2026 No acquisitions took place during the third quarter that had a material impact on the Group’s financial earnings and position . Contingent considerations Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilitie s for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. Th e additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the ear nings performance of the acquired businesses. Future cash flows are discounted if the planned payment date ex ceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing bas is. Contingent considerations September 30 2026 September 30 2025 December 31 2025 Opening balance 1,444 3,280 3,280 Dissolution of provision - - - 55 Fair value adjustments recognized in profit or loss - 5 184 Payments - 1,040 - 1,599 - 1,599 Discount effect 22 60 77 Translation differences 64 - 401 - 443 Closing balance 490 1,344 1,444 Parent Company financial statements Condensed Parent Company’s income statement SEK M Jul - Sep 2026 Jul - Sep 2025 Jan - Sep 2026 Jan - Sep 2025 Jan - Dec 2025 Net sales 84 75 263 257 348 Administrative expenses - 135 - 86 - 373 - 282 - 397 Operating profit/loss - 51 - 11 - 110 - 25 - 49 Result from participations in Group companies 1) 58 43 1,487 2,134 2,134 Interest income and other similar income 2) 1 8 8 45 55 Interest expenses and other similar expenses 2) - 50 - 54 - 150 - 167 - 220 Profit after financial items - 42 - 14 1,235 1,987 1,920 Appropriations 0 - 0 - 60 Taxes 10 2 11 - 6 - 24 Net profit/loss for the period 3) - 32 - 12 1,246 1,981 1,956 1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year 2) Interest income and other similar income, and interest expenses and other similar expenses include exchange - rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies 3) Comprehensive income for the period corresponds to net profit for the period

Page 25

25 | Q3 2026 Report Condensed Parent Company’s balance sheet SEK M September 30 2026 September 30 2025 December 31 2025 Assets Tangible assets 1 1 1 Participations in Group companies 31,604 31,572 31,572 Deferred tax assets 120 104 97 Current receivables from Group companies 817 1,222 974 Current receivables 84 80 40 Cash and bank balances 0 2 2 Total assets 32,626 32,981 32,687 Equity and liabilities Equity 26,325 26,397 26,372 Long - term liabilities 4,645 5,793 5,394 Other provisions 32 25 18 Current liabilities to Group companies 2 8 7 Current liabilities 1,623 758 896 Total equity and liabilities 32,626 32,981 32,687

Page 26

26 | Q3 2026 Report Definitions Financial terms Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares. Adjusted EBIT: Operating profit (EBIT) with add - back of acquisition and restructuring costs, and other items affecting comparability. Adjusted EBITA: EBITA with add - back of acquisition and restructuring costs and other items affecting comparability. Adjusted EBITDA: EBITDA with add - back of acquisition and restructuring costs and other items affecting comparability. Adjusted gross profit: Gross profit with add - back of depreciation, amortization and write - downs and other items affecting comparability. Adjusted net profit for the period: Net profit for the period with add - back of amortization and write - down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add - back of income - statement items. Adjusted profit before tax: Profit before tax for the period with add - back of amortization and write - down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability. Capital employed: Average total assets with add - back of cash and cash equivalents, other provisions, accounts payable and other non - interest - bearing liabilities. Capital goods : Durable products that are not consumed when used. Currency transaction effect: Exchange of current year’s volumes of foreign currency at this year’s exchange rates, compared with the exchange rates in the preceding year. Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares. EBIT: Operating profit. EBITA margin: EBITA in relation to net sales. EBITA: Operating profit (EBIT) before add - back of amortization and write - down of acquired intangible assets. EBITDA margin : EBITDA in relation to net sales. EBITDA: Operating profit (EBIT) with add - back of amortization, depreciation and write - downs. Equity per share: Equity in relation to the number of shares at the end of the period. Equity/assets ratio: Equity in relation to total assets. Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations. Gross margin: Gross profit in relation to net sales. Interest - coverage ratio: Rolling 12 months’ adjusted EBITDA in relation to rolling 12 months’ net interest. Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write - downs , disputes and major gains and losses attributable to divestments of assets or businesses. Net debt/equity ratio: Net interest - bearing debt in relation to equity. Operating liabilities: Accounts payable, other provisions and other non - interest - bearing liabilities (contract liabilities, non - interest - bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities). Operating margin: Operating profit (EBIT) in relation to net sales. Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables). Organic change: A financial change adjusted for currency, acquisitions and divestments of operations. Adjusted to the following from first quarter of 2026: A financial change adjusted for currency, acquisitions and divestments of operations and phase - out of product categories . Recurring revenue : Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items. Return on capital employed: Rolling 12 months’ adjusted EBIT in relation to capital employed. Return on equity: Rolling 12 months’ profit after tax in relation to average equity. Sustainability terms Double materiality assessment: The process of identifying an organization’s impacts on people and the environment and the sustainability - related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be includ ed in the company’s sustainability report. Employee engagement: The engagement score in Getinge’s employee survey. ESRS: European Sustainability Reporting Standards. Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e - learning course or participated in a training webinar. REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources. Scope 1 & 2: Carbon emissions from production (in ton CO 2 equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge’s vehicle fleet are excluded in the interim report but the amounts for the full - year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full - year are presented in the Sustainability Report. Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold. WRAR (Work Related Accident Rate): The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours. Medical terms Autoclave: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam. Cardiopulmonary: Pertaining or belonging to both heart and lung. Cardiovascular: Pertaining or belonging to both heart and blood vessels. DPTE® - BetaBags: Bag that ensures contamination - free transfer of components. ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine

Page 27

27 | Q3 2026 Report that exchanges oxygen and carbon dioxide, like an artificial lung. Endoscope: Equipment for visual examination of the body’s cavities, such as the stomach. Endovascular: Vascular treatment using catheter technologies. EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery. Extracorporal life support (ECLS): Oxygenation of the patient’s blood outside the body (extracorporeal) using advanced medical technology. Grafts: Artificial vascular implants. Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow. Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery. NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient’s respiratory rhythm. Perfusionist: A healthcare professional who operates the heart - lung machine during surgery. Stent: A tube for endovascular widening of blood vessels. Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method. Ventilator: Medical device to help patients breath. Vessel harvesting: The name of the process for removing blood vessels from the body. WIS: The product category of washers, isolators and sterilizers. Geographic areas Americas: North, South and Central America. APAC: Asia and Pacific (excluding Middle East). EMEA: Europe, Middle East and Africa.

Page 28

28 | Q3 2026 Report Teleconference A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on October 21, 2026 at 10:00 – 11:00 a.m. CEST. Fund managers, analysts and the media are invited to the teleconference. Register via https://events.inderes.com/getinge/q3 - 2026/dial - in to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference. A presentation will be held during the telephone conference. To access the presentation, click on https://getinge.events.inderes.com/q3 - 2026 . A recording will be available via https://getinge.events.inderes.com/q3 - 2026 for three years. Financial information Updated information on, for example, the Getinge share and corporate governance is available on Getinge’s website www.getinge .com. The Annual Report, year - end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below: January 26, 2027 Q4 and Year - end report 2026 April 20, 2027 Q1 Report 2027 April 20, 2027 Annual General Meeting July 16, 2027 Q2 Report 2027 October 19, 2027 Q3 Report 2027 January 25, 2028 Q4 and Year - end report 2027 Contact David Kördel, Head of Investor Relations +46 (0)10 335 0077 david.kordel@getinge.com This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. T he information was submitted for publication, through the agency of the contact persons set out above, on October 21, 2026 at 8:00 a.m. CEST. Getinge AB (publ) │ Lindholmspiren 7A, 417 56 Gothenburg, Sweden │ Tel: +46 (0)10 335 0000 │ E - mail: info@getinge.com │ Corp. Reg. No.: 556408 - 5032 │ www.getinge.com With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals a nd life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries. Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.

Interim report

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

Page 7

Page 8

Page 9

Page 10

Page 11

Page 12

Page 13

Page 14

Page 15

Page 16

Page 17

Page 18

Page 19

Page 20

Page 21

Page 22

Page 23

Page 24

Page 25

Page 26

Page 27

Page 28

Sign in to continue

Interim report

Page 1

Page 2

Page 3

Page 4

Page 5

Page 6

Page 7

Page 8

Page 9

Page 10

Page 11

Page 12

Page 13

Page 14

Page 15

Page 16

Page 17

Page 18

Page 19

Page 20

Page 21

Page 22

Page 23

Page 24

Page 25

Page 26

Page 27

Page 28

Sign in to continue